Nasdaq:US$15.81 (-0.23) | HKEX:HK$24.35 (-0.50) | AIM:£2.54 (-0.05)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer